12:01 PM
 | 
Feb 16, 2018
 |  BC Week In Review  |  Company News  |  Deals

Sirenas, BMS partner on drug discovery for "challenging" targets

Sirenas LLC (San Diego, Calif.) and Bristol-Myers Squibb Co. (NYSE:BMY) partnered to use Sirenas' ATLANTIS drug discovery platform against several undisclosed "challenging" targets.

ATLANTIS uses machine learning to discover microbiome-derived metabolites,...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >